Nasal vaccines

Advanced Drug Delivery Reviews

Volumn 51, Issue 1-3, 2001, Pages 21-42

  Davis, S S ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Common mucosal immune system; Nasal vaccines; Nose associated lymphoid tissue; Tonsils; Waldeyer's ring

Indexed keywords

ANTIGENS; IMMUNOLOGY; PHYSIOLOGY; PULMONARY DISEASES; RESPIRATORY THERAPY; TISSUE;

NASAL ROUTE;

VACCINES;

BCG VACCINE; CHIMERIC PROTEIN; CHOLERA TOXIN; ISCOM; LIPOSOME; MICROSPHERE; VACCINE;

BACTERIAL INFECTION; HUMAN; IMMUNE RESPONSE; LYMPHOID TISSUE; MUCOCILIARY CLEARANCE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYSTEM; REVIEW; SPECIES DIFFERENCE; TONSIL; VACCINATION; WALDEYER RING;

ADMINISTRATION, INTRANASAL; ANIMALS; HUMANS; IMMUNITY, MUCOSAL; LUNG; LYMPHOID TISSUE; NASAL MUCOSA; VACCINATION; VACCINES;

EID: 0035940309     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(01)00162-4     Document Type: Review

References (176)

1. Current options for vaccine delivery systems by mucosal routes
2. Mucosal vaccines: An overview
3. Induction of mucosal immune responses against a heterologous antigen fused to filamentous hemagglutinin after intranasal immunization with recombinant Bordetella pertussis
4. Intranasal vaccines: Forthcoming challenges
5. Nasal-associated lymphoid tissue
6. Intra-epithelial lymphocytes and non-lymphoid cells in the human nasal mucosa
7. Analysis of local and systemic immunological responses after intra-tracheal, intra-nasal and intra-muscular administration of microsphere co-encapsulated Yersinia pestis subunit vaccines
8. In vivo characterization of the murine intranasal model for assessing the immunogenicity of attenuated Salmonella enterica Serovar Typhi strains as liver mucosal vaccines and as live vectors
9. Regional specialization in the mucosal immune system: What happens in the microcompartments?
10. Regional specialization in the mucosal immune system: Primed cells do not always home along the same track
11. Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit
12. Epithelial disposition of antigen
13. Clearance of inhaled particles from the human nose
14. Respiratory tract defenses: Role of mucosal lymphoid tissues
15. Mucosal immune responses - An overview
16. Larynx-associated lymphoid tissue (LALT) in young children
17. Bronchus-associated lymphoid tissue (BALT) and larynx-associated lymphoid tissue (LALT) are found at different frequencies in children, adolescents and adults
18. The role of nasopharyngeal lymphoid tissue
19. Targeted delivery of antigen to hamster nasal lymphoid tissue with M-cell directed lectins
20. Reticulum cells in the ontogeny of nasal-associated lymphoid tissue (NALT) in the rat
21. Microvascular architecture of rat nasal associated lymphoid tissue
22. IgA antibody-forming cell responses in the nasal-associated lymphoid tissue of mice vaccinated by intranasal, intravenous and/or subcutaneous administration
23. Immunology of the tonsils
24. Identification of M-cells in the rabbit tonsil by vimentin immunohistochemistry and in vivo protein transport
25. Evidence of M cells as portals of entry for antigens in the nasopharyngeal lymphoid tissue of humans
26. Cathepsin E in follicle associated epithelium of intestine and tonsils: Localization to M cells and possible role in antigen processing
27. The immunobiology of the tonsils and adenoids
28. The hidden tonsils of Waldeyer's ring
29. The influence of tonsillectomy on cell-mediated immune response
30. Mucosal immunoprophylaxis: An introductory overview
31. Changes in immunological response in tonsillectomized children. II. Decreased cellular response
32. Serum immunoglobulins and secretory IgA deficiency in tonsillectomized children
33. Nasal lymphoid tissue (NALT) as a mucosal immune inductive site
34. Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system
35. Patterns of lymphatic drainage in the adult laboratory rat
36. Nasopharyngeal-associated lymphoreticular tissue (NALT) immunity: Fimbriae-specific Th1 and Th2 cell-regulated IgA responses for the inhibition of bacterial attachment to epithelial cells and subsequent inflammatory cytokine production
37. Nasal immune system: Distinctive Th0 and Th1/Th2 type environments in murine nasal-associated lymphoid tissues and nasal passage, respectively
38. Inducing tolerance by intranasal administration of long peptides in naïve and primed CBA/J mice
39. Is BALT a major component of the human lung immune system?
40. Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes
41. Intranasal immunization with heat-inactivated Streptococcus pneumoniae protects mice against systemic pneumococcal infection
42. Nasal immunization with group B streptococci can induce high levels of specific IgA antibodies in cervicovaginal secretions of mice
43. Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes simplex virus glycoprotein B
44. Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus
45. Strategies of immunization against mucosal infections
46. The nasopharynx and the middle ear. Inflammatory reactions in middle ear disease
47. Intranasal immunization against influenza virus using polymeric particles
48. Antipeptide antibody responses following intranasal immunization: Effective mucosal adjuvants
49. Immunological responses to nasal delivery of free and encapsulated tetanus toxoid: Studies on the effect of vehicle volume
50. Single-dose mucosal immunization with biodegradable microparticles containing a Schistosoma mansoni antigen
51. Induction of mucosal and systemic antibody specific for SeMF3 of Streptococcus equi by intranasal vaccination using a sucrose acetate isobutyrate based delivery system
52. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants
53. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease
54. Vaccine safety
55. Live cold-adapted, reassortant influenza vaccines (USA)
56. The nasal secretion and serum antibody response of lambs following vaccination and aerosol challenge with parainfluenza 3 virus
57. An experimental influenza subunit vaccine (iscom): Induction of protective immunity to challenge infection in mice after intranasal or subcutaneous administration
58. Initiation of cytotoxic T-cell response and protection of Balb/c mice by vaccination with an experimental ISCOMs respiratory syncytial virus subunit vaccine
59. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models
60. Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi
61. Activation of systemic and mucosal immune response following nasal administration of liposomes
62. Mucosal and systemic immune responses to a recombinant protein expressed on the surface of the oral commensal bacterium Streptococcus gordonii after oral colonization
63. Induction of protective antibody responses against pseudorabies virus by intranasal vaccination with glycoprotein B in mice
64. Prevention of influenza by the intranasal administration of cold-recombinant, live-attenuated influenza virus vaccine: Importance of interferon-γ production and local IgA response
65. Induction of systemic immune responses to measles virus synthetic peptides administered intranasally
66. Induction of systemic and mucosal immune responses following immunization with somatostatin-avidin complexes incorporated into ISCOMS
67. Immune responses and protection against Bordella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles
68. Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus
69. Liposomes as an immunoadjuvant system for stimulation of mucosal and systemic antibody reponses against inactivated measles virus administered intranasally to mice
70. The adjuvant effect of a non-toxic mutant of heat-labile enterotoxin of Escherichia coli for the induction of measles virus-specific CTL responses after intranasal co-immunisation with a synthetic peptide
71. Linkage of a fusion peptide to a CTL epitope from the nucleoprotein of measles virus enables incorporation into ISCOMS and induction of CTL responses following intranasal immunisation
72. Unilateral nasal infection of cotton rats with respiratory syncytial virus allows assessment of local and systemic immunity
73. Intranasal immunization induces long-term protection in mice against a Chlamydia trachomatis genital challenge
74. Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization
75. Induction of mucosal immune responses against a heterologous antigen fused to filamentous hemagglutinin after intranasal immunization with recombinant Bordetella pertussis
76. Nasal immunization with group B streptococci can induce high levels of specific IgA antibodies in cervicovaginal secretions of mice
77. Protective responses in mice to vaccination with multiple administered cold-adapted influenza vaccine reassortants and wild-type viruses
78. Protection against tetanus toxin in mice nasally immunized with recombinant Lactococcus lactis expressing tetanus toxin fragment C
79. A nasal whole-cell pertussis vaccine can induce strong systemic and mucosal antibody responses which are not enhanced by cholera toxin
80. Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina
81. Intranasal booster vaccination against diphtheria and tetanus in man
82. A murine model of intranasal immunization to assess the immunogenicity of attenuated Salmonella typhi live vector vaccines in stimulating serum antibody responses to expressed foreign antigens
83. Intranasal immunization of mice with Echinococcus granulosus surface antigens iscoms evokes a strong immune response, biased towards glucidic epitopes
84. Recombinant bacille Calmette-Guérin expressing the measles virus nucleoprotein protects infant rhesus macaques from measles virus pneumonia
85. Intranasal priming with recombinant Bordetella pertussis for the induction of a systemic immune response against a heterologous antigen
86. Systemic and mucosal immune responses after intranasal administration of recombinant Mycobacterium bovis bacillus Calmette-Guérin expressing glutathione S-transferase from Schistosoma haematobium
87. Specific mucosal immunity and enhanced nasopharyngeal clearance of nontypeable Haemophilis influenzae after intranasal immunization with outer membrane protein P6 and cholera toxin
88. Mucosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: Induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen
89. Intranasal immunization with Yersinia enterocolitica 0:8 cellular extract protects against local challenge infection
90. c expressing urease A and B subunits
91. Analysis of local and systemic immunological responses after intra-tracheal, intra-nasal and intra-muscular administration of microsphere co-encapsulated Yersinia pestis sub-unit vaccines
92. IgA antibody-forming cell responses in the nasal-associated lymphoid tissue of mice vaccinated by intranasal, intravenous and/or subcutaneous administration
93. A mucosal IgA response, but no systemic antibody response, is evoked by intranasal immunisation of dogs with Echinococcus granulosus surface antigens iscoms
94. Intranasal immunization with polymer-grafted microparticles activates the nasal-associated lymphoid tissue and draining lymph nodes
95. Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice
96. The immunostimulatory complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses
97. Intranasal administration of human immunodeficiency virus type-1 (HIV-1) DNA vaccine with interleukin-2 expression plasmid enhances cell-mediated immunity against HIV-1
98. Polymer-grafted starch microparticles for oral and nasal immunization
99. Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: The effect of adjuvants on mucosal and serum antibody responses
100. Bordetella pertussis filamentous hemagglutinin enhances the immunogenicity of liposome-delivered antigen administered intranasally
101. Homologous and heterologous protection after single intranasal administration of live attenuated recombinant Bordetella pertussis
102. Protection against measles virus-induced encephalitis by antibodies from mice immunized intranasally with a synthetic peptide immunogen
103. Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans
104. Enhancement of immune response to intranasal influenza HA vaccine by microparticle resin
105. Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugates
106. Reduction of respiratory syncytial virus titer in the lungs of mice after intranasal immunization with a chimeric peptide consisting of a single CTL epitope linked to a fusion peptide
107. Intranasal immunisation with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunisation
108. Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts
109. A controlled clinical study of the effect of nasal immunization with a Streptococcus mutans antigen alone or incorporated into liposomes on induction of immune responses
110. Outer membrane vesicles from group B meningococci are strongly immunogenic when given intranasally to mice
111. Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes
112. Intranasal immunization with heat-inactivated Streptococcus pneumoniae protects mice against systemic pneumococcal infection
113. Immunogenicity of intranasally administered meningococcal native outer membrane vesicles in mice
114. Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccine
115. The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice
116. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: Differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells
117. Mucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of mice
118. Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers
119. Nasal immunization induces Haemophilis influenzae-specific Th1 and Th2 responses with mucosal IgA and systemic IgG antibodies for protective immunity
120. Mutants of cholera toxin as an effective and safe adjuvant for nasal influenza vaccine
121. Complete protection of mice from respiratory syncytial virus infection following mucosal delivery of synthetic peptide vaccines
122. A surface-displayed cholera toxin B peptide improves antibody responses using food-grade staphylocci for mucosal subunit vaccine delivery
123. Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit
124. Novel modifications to the C-terminus of LTB that facilitate site-directed chemical coupling of antigens and the development of LTB as a carrier for mucosal vaccines
125. Nasal and parenteral immunizations with diphtheria toxoid using monoglyceride/fatty acid lipid suspensions as adjuvants
126. Adjuvant activity of immunopotentiating reconstituted influenza virosomes (IRIVs)
127. Intra-nasal infection of macaques with Yellow Fever (YF) vaccine strain 17D: A novel and economical approach for YF vaccination in man
128. IL-12 is an effective adjuvant for induction of mucosal immunity
129. Use of intranasal IL-12 to target predominantly Th1 responses to nasal and Th2 responses to oral vaccines given with cholera toxin
130. Chimeric plant virus particles administered nasally or orally induce systemic and mucosal immune responses in mice
131. Induction of mucosal immune responses by administration of liposome-antigen formulations and interleukin-12
132. Respiratory viral infections in the elderly
133. A novel and effective intranasal immunization strategy for respiratory syncytial virus
134. Selection of the most efficacious of twenty-two inactivated Sendai virus nasal vaccines by determination of the protection index in mice
135. The nature of the attenuation of Salmonella typhimurium strains expressing human papillomavirus type 16 virus-like particles determines the systemic and mucosal antibody responses in nasally immunized mice
136. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2) and B viruses
137. Intranasal immunization of mice with influenza vaccine in combination with the adjuvant LT-R72 induces potent mucosal and setum immunity which is stronger than that with traditional intramuscular immunization
138. Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers
139. Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpes simplex virus type 2 in guinea pigs
140. Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts
141. A controlled clinical study of the effect of nasal immunization with a Streptococcus mutans antigen alone or incorporated into liposomes on induction of immune responses
142. Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers
143. Nasal immunization of mice with Cryptosporidium parvum DNA induces systemic and intestinal immune responses
144. Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity
145. Evaluation of a live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccine candidate in infancy
146. Approaches to improved influenza vaccination
147. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine
148. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults
149. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine
150. Nasal immunization of mice with virus-like particles protects offspring against rotavirus diarrhea
151. In vivo characterization of the murine intranasal model for assessing the immunogenicity of attenuated Salmonella enterica Serovar Typhi strains as live mucosal vaccines and as live vectors
152. Fragilysin, the enterotoxin from Bacteroides fragilis, enhances the serum antibody response to antigen co-administered by the intranasal route
153. Partial protection to respiratory syncytial virus (RSV) elicited in mice by intranasal immunization using live staphylococci with surface-displayed RSV-peptides
154. ΔguaBA attenuated Shigella flexneri 2a strain CVD 1204 as a Shigella vaccine and as a live mucosal delivery system for fragment C of tetanus toxin
155. Combined nasal administration of encephalitogeic myelin basic protein peptide 68-86 and IL-10 suppressed incipient experimental allergic encephalomyelitis in Lewis rats
156. Effectiveness of intranasal immunization with HIV-gp160 and an HIV-1 Env CTL epitope peptide (E7) in combination with the mucosal adjuvant LT(R192G)
157. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant
158. 197) of diphtheria toxin with chitosan enhances local and systemic antibodies and Th2 responses following nasal delivery
159. Intranasal immunization with liposome-formulated Yersinia pestis vaccine enhances mucosal immune responses
160. Naked DNA when co-administered intranasally with heat-labile enterotoxin of Escherichia coli primes effectively for systemic B- and T-cell responses to the encoded antigen
161. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration
162. Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen
163. Engineering the microflora to vaccinate the mucosa: Serum immunoglobulin G responses and activated draining cervical lymph nodes following mucosal application of tetanus toxin fragment C-expressing lactobacilli
164. Hyaluronic acid biopolymers for mucosal delivery of vaccines
165. Intranasal immunization with protein-linked phosphorylcholine protects mice against a lethal intranasal challenge with Streptococcus pneumoniae
166. Genital antibody responses in mice after intranasal infection with an attenuated candidate vector strain of Bordetella pertussis
167. Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins
168. Induction of antigen-specific T cell responses in human volunteers after intranasal immunization with a whole-cell pertussis vaccine
169. Inactivated meningococci and pertussis bacteria are immunogenic and act as mucosal adjuvants for a nasal inactivated influenza virus vaccine
170. A nasal whole-cell pertussis vaccine induces specific systemic and cross-reactive mucosal antibody responses in human volunteers
171. The comparison of the effect of LTR72 and MF 59 adjuvants on mouse humoral response to intranasal immunisation with human papillomavirus type 6b (HPV-6b) virus-like particles
172. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization
173. Mucosal immunization against hepatitis B virus by intranasal co-administration of recombinant hepatitis B surface antigen and recombinant cholera toxin B subunit as an adjuvant
174. Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies
175. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants
176. Potency of a genetically toxoided mucosal adjuvant derived from the heat-labile enterotoxin of E. coli (LTK63) is not adversely affected by the presence of pre-existing immunity to the adjuvant